Generation of pralatrexate resistant T‐cell lymphoma lines reveals two patterns of acquired drug resistance that is overcome with epigenetic modifiers

While pralatrexate (PDX) has been successfully developed for the treatment of T‐cell lymphoma, the mechanistic basis for its T‐cell selectivity and acquired resistance remains elusive. In an effort to potentially identify synergistic combinations that might circumnavigate or delay acquired PDX resis...

Descripción completa

Detalles Bibliográficos
Autores principales: Scotto, Luigi, Kinahan, Cristina, Casadei, Beatrice, Mangone, Michael, Douglass, Eugene, Murty, Vundavalli V., Marchi, Enrica, Ma, Helen, George, Changchun, Montanari, Francesca, Califano, Andrea, O'Connor, Owen A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2020
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7540375/
https://www.ncbi.nlm.nih.gov/pubmed/32614991
http://dx.doi.org/10.1002/gcc.22884

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7540375/
https://www.ncbi.nlm.nih.gov/pubmed/32614991
http://dx.doi.org/10.1002/gcc.22884

Ejemplares similares